From April 1, 2023 to June 30, 2023, the company has repurchased 173,900 shares, representing 1.44% for CAD 1.28 million. With this, the company has completed the repurchase of 226,700 shares, representing 1.87% for CAD 1.67 million under the buyback announced on December 13, 2022.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
9 CAD | 0.00% | +7.53% | -2.39% |
05-17 | BioSyent Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
05-17 | BioSyent Inc Declares Second Quarter 2024 Dividend, Payable June 15, 2024 | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-2.39% | 76.41M | |
+37.78% | 723B | |
+31.31% | 598B | |
-3.51% | 364B | |
+19.94% | 331B | |
+5.14% | 288B | |
+15.92% | 244B | |
+9.61% | 210B | |
-5.03% | 208B | |
+9.32% | 169B |
- Stock Market
- Equities
- RX Stock
- News BioSyent Inc.
- Tranche Update on BioSyent Inc. (TSXV: RX)'s Equity Buyback Plan announced on December 13, 2022.